Brian Broberg
Brian Broberg
CNSR
Adresse e-mail validée de cnsr.dk
Titre
Citée par
Citée par
Année
Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia
MO Nielsen, E Rostrup, S Wulff, N Bak, BV Broberg, H Lublin, S Kapur, ...
Archives of general psychiatry 69 (12), 1195-1204, 2012
1302012
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study
RS Kahn, IW van Rossum, S Leucht, P McGuire, SW Lewis, M Leboyer, ...
The Lancet Psychiatry 5 (10), 797-807, 2018
992018
Evaluation of a neurodevelopmental model of schizophrenia—early postnatal PCP treatment in attentional set-shifting
BV Broberg, R Dias, BY Glenthøj, CK Olsen
Behavioural brain research 190 (1), 160-163, 2008
812008
The Rho kinase inhibitor Fasudil up‐regulates astrocytic glutamate transport subsequent to actin remodelling in murine cultured astrocytes
CL Lau, RD O'shea, BV Broberg, L Bischof, PM Beart
British journal of pharmacology 163 (3), 533-545, 2011
742011
Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1 H-MRS study (OPTiMiSE)
A Egerton, BV Broberg, N Van Haren, K Merritt, GJ Barker, DJ Lythgoe, ...
Molecular psychiatry 23 (11), 2145-2155, 2018
652018
Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia—sub-chronic and early postnatal PCP treatment in attentional set …
BV Broberg, BY Glenthøj, R Dias, DB Larsen, CK Olsen
Psychopharmacology 206 (4), 631-640, 2009
652009
Effects of lipopolysaccharide on glial phenotype and activity of glutamate transporters: evidence for delayed up-regulation and redistribution of GLT-1
RD O'Shea, CL Lau, MC Farso, S Diwakarla, CJ Zagami, BB Svendsen, ...
Neurochemistry international 48 (6-7), 604-610, 2006
612006
Differential expression of parvalbumin in neonatal phencyclidine‐treated rats and socially isolated rats
SS Kaalund, J Riise, BV Broberg, K Fabricius, AS Karlsen, T Secher, ...
Journal of neurochemistry 124 (4), 548-557, 2013
412013
Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis
D Siskind, M Hahn, CU Correll, A Fink‐Jensen, AW Russell, N Bak, ...
Diabetes, Obesity and Metabolism 21 (2), 293-302, 2019
382019
Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial
PL Ishøy, FK Knop, BV Broberg, N Bak, UB Andersen, NR Jørgensen, ...
Diabetes, Obesity and Metabolism 19 (2), 162-171, 2017
322017
Towards precision medicine in psychosis: benefits and challenges of multimodal multicenter studies—PSYSCAN: translating neuroimaging findings from research into clinical practice
S Tognin, HH van Hell, K Merritt, I Winter-van Rossum, MG Bossong, ...
Schizophrenia bulletin 46 (2), 432-441, 2020
282020
Impaired GABAergic inhibition in the prefrontal cortex of early postnatal phencyclidine (PCP)-treated rats
C Kjaerby, BV Broberg, U Kristiansen, NO Dalby
Cerebral cortex 24 (9), 2522-2532, 2014
282014
Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia—gating of auditory-evoked potentials and prepulse inhibition
BV Broberg, B Oranje, BY Glenthøj, K Fejgin, N Plath, JF Bastlund
Behavioural brain research 213 (2), 142-147, 2010
252010
No cognitive‐enhancing effect of GLP‐1 receptor agonism in antipsychotic‐treated, obese patients with schizophrenia
PL Ishøy, B Fagerlund, BV Broberg, N Bak, FK Knop, BY Glenthøj, ...
Acta Psychiatrica Scandinavica 136 (1), 52-62, 2017
222017
Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded …
PL Ishøy, FK Knop, BV Broberg, L Baandrup, B Fagerlund, NR Jørgensen, ...
BMJ open 4 (1), 2014
192014
Multiple measures of HPA axis function in ultra high risk and first-episode schizophrenia patients
D Nordholm, E Rostrup, V Mondelli, L Randers, MØ Nielsen, S Wulff, ...
Psychoneuroendocrinology 92, 72-80, 2018
182018
Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis
KB Bojesen, BH Ebdrup, K Jessen, A Sigvard, K Tangmose, RAE Edden, ...
Psychological medicine 50 (13), 2182-2193, 2020
162020
Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a 1 [H]-spectroscopy twin study
CS Legind, BV Broberg, RCW Mandl, R Brouwer, SJ Anhøj, R Hilker, ...
Neuropsychopharmacology 44 (3), 581-589, 2019
162019
Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of 1H-MRS studies
C Wenneberg, BY Glenthøj, C Hjorthøj, FJB Zingenberg, LB Glenthøj, ...
Schizophrenia research 215, 38-48, 2020
152020
A schizophrenia rat model induced by early postnatal phencyclidine treatment and characterized by Magnetic Resonance Imaging
BV Broberg, KH Madsen, N Plath, CK Olsen, BY Glenthøj, OB Paulson, ...
Behavioural brain research 250, 1-8, 2013
152013
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20